BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

Hugdahl, Emilia; Kalvenes, May Britt; Puntervoll, Hanne; Ladstein, Rita Grude; Akslen, Lars A.

doi:10.1038/bjc.2016.44

Cited by 62 publications

(80 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these studies concluded that BRAF mutation was in association with younger age at diagnosis (Heppt et al, ; Hugdahl et al, ; Meckbach et al, ), truncal lesion (Heppt et al, ; Hugdahl et al, ), and the superficially spreading melanoma histotype (Heppt et al, ; Meckbach et al, ), we agree with these findings. Regarding major prognostic indicators, precious studies demonstrated BRAF‐mutant melanomas were correlated with increased tumor thickness (Ellerhorst et al, ; Hugdahl et al, ), higher mitotic count (Ellerhorst et al, ; Hugdahl et al, ; Long et al, ; Meckbach et al, ) and presence of ulceration (Akslen et al, ; Ellerhorst et al, ; Hugdahl et al, ). Conversely, we found no similar associations in our patients.…”

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

“…Many studies have investigated the association between BRAF mutation and clinicopathological features in melanoma (Akslen et al, ; Ellerhorst et al, ; Heppt et al, ; Hugdahl et al, ; Inumaru et al, ; Maldonado et al, ; Mann et al, ; Meckbach et al, ; Moreau et al, ; Picard et al, ; Shinozaki et al, ). Most of these studies concluded that BRAF mutation was in association with younger age at diagnosis (Heppt et al, ; Hugdahl et al, ; Meckbach et al, ), truncal lesion (Heppt et al, ; Hugdahl et al, ), and the superficially spreading melanoma histotype (Heppt et al, ; Meckbach et al, ), we agree with these findings. Regarding major prognostic indicators, precious studies demonstrated BRAF‐mutant melanomas were correlated with increased tumor thickness (Ellerhorst et al, ; Hugdahl et al, ), higher mitotic count (Ellerhorst et al, ; Hugdahl et al, ; Long et al, ; Meckbach et al, ) and presence of ulceration (Akslen et al, ; Ellerhorst et al, ; Hugdahl et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…The prognostic significance of BRAF mutations in the natural course of melanoma is controversial (Ardekani et al, ; Edlunch‐Rose et al, ; Hugdahl, Kalvenes, Puntervoll, Ladstein, & Akslen, ; Long et al, ; Menzies et al, ). Some studies showed poor survivals in metastatic BRAF‐mutant patients (Ardekani et al, ; Long et al, ; Menzies et al, ), whereas others found no association between the tumor BRAF genotype and survival in metastatic settings (Edlunch‐Rose et al, ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

Taş

Ertürk

2020

Dermatologic Therapy

View full text Add to dashboard Cite

The prognostic significance of BRAF mutations in the natural course of melanoma is controversial. The aim of study was to assess the prognostic significance of BRAF V600E mutation in cutaneous melanoma patients. A total of 151 melanomas were included in the study. BRAF V600E mutation was detected using the real‐time PCR. BRAF V600E mutation rate was 51%. BRAF mutation rate was higher for young patients (61.4%) and upper limbs (63.2%), trunk (59.3%) and head and neck (59.2%) were the most frequently afflicted sites in BRAF‐mutant patients, whereas lower limbs were mostly affected in BRAF‐wild patients (77.8%). Likewise, acral melanomas rarely harbored BRAF mutation (17.1%). The disease‐free survivals regarding the entire and Stage III cohorts were longer in the BRAF‐mutant group than in the BRAF‐wild group (p = .006 and p = .004, respectively), whereas Stage I–II patients had no survival differences between BRAF statuses (p = .2). Likewise, BRAF‐mutant patients had better overall survival (OS) time compared to BRAF‐wild patients in all stages (p = .01), in Stage III (p = .01), and in Stage IV patients (p = .001). However, no differences between BRAF statuses were observed in Stage I–II melanomas (p = .3). In conclusion, BRAF V600E‐mutant melanomas show favorable prognostic impact on both disease‐free and OSs in all staged melanomas except local disease.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

Taş

Ertürk

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Also, a study by Hughahl et al (22) revealed the association between higher rates of BRAF V600 immunohistochemistry expression and increased tumour thickness, presence of ulceration and higher rates of mitosis. Conversely, several papers have declared that the BRAF V600 mutation has no impact on clinicopathological features or survival (22)(23)(24)(25)(26). Although there was no significant correlation in the present study, the patients with the BRAF V600 mutation were younger than the patients with wild-type BRAF, and NM was detected more commonly in BRAF V600-mutated patients.…”

Section: Discussionmentioning

confidence: 98%

Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Can¹,

Taştekin²,

Yalta³

et al. 2018

TJPATH

View full text Add to dashboard Cite

Objective: BRAF is the most common mutation in melanoma. The most common subtype is BRAF V600E, followed by V600K. Initially, the authors aimed to investigate whether clinicopathological features of melanoma are associated with BRAF mutations. We then aimed to present the relationships between the clinicopathological features and the mutated subtype (V600E vs V600K). Material and Method:61 patients with metastatic malignant melanoma (affecting the lymph node or other distant sites) were selected. Patient data regarding age at the time of diagnosis, sex, metastatic site (lymph node, distant metastasis or both) and primary tumour site were obtained from the hospital's database. Tissue samples containing at least 30% tumour cells were isolated from the specimens of 61 patients (24 samples from primary tumours and 37 from metastatic foci) for BRAF analysis. Comparisons between the BRAF V600 mutation and clinicopathological and histopathological features were performed.Results: BRAF V600 mutation was detected in 34 (55.7%) patients. The subtype was BRAF V600E in 22 (64.7%) patients, BRAF V600K in 11(32.4%) patients and BRAF V600R in 1(2.9%) patient. The crucial results of the present study may be summarized as follows: i) BRAF V600 mutation was more common in older patients and tumors with BRAF V600 mutation revealed necrosis and LVI more commonly than wild-type tumors, ii) BRAF V600K mutation was more common in older patients and BRAF V600K mutated tumors exhibited ulceration more commonly than tumors with BRAF V600E mutation (close to significant). Conclusion:The BRAF V600 mutation may have interactions with prognostic clinicoptahological features of melanoma including necrosis and lymphovascular invasion. V600K mutation may be more common than expected and may have different associations with properties of the tumor such as tumor ulceration and patient age. Investigation of the mutated subtype of the BRAF gene may therefore reveal more detailed data about the management of melanoma and may also prevent missing of candidates for BRAF inhibitor therapies.

show abstract

Nodular melanoma in an African American Japanese male

Gonzalez

King

Moossavi

2023

Clinical Case Reports

View full text Add to dashboard Cite

Malignant melanoma is a rare disease in the non-Caucasian population. The US Surveillance, Epidemiology, and End Results (SEER) registry, containing data from 1988 to 2011 demonstrated that in men, incidence of melanoma in Caucasians is 33 per 100,000 compared to 1.2 and 0.9 in African Americans (AA) and Asians, respectively. 1,2 Acral lentiginous melanoma (ALM) was overwhelmingly the most common subtype of melanoma in African Americans: 18.0% of the cases were ALM compared to 0.91% in Caucasians. 55.9% of the cases in African Americans were classified as melanoma not otherwise specified (NOS). The second and third most common subtypes in African Americans were superficial spreading melanoma (SSM) and nodular melanoma (NM), comprising 15.6% and 7.9% of the cases during the 23-year period, respectively. In some studies, the incidence of melanoma is noted to be twice as high in the Japanese as compared to other Asian races. 2,3 The World Health Organization (WHO) demonstrated the incidence of melanoma in Japan to be 0.3 and 0.8 per 100,000 in male and female, respectively. 4 In contrast, hospital cancer registries in Japan demonstrate the annual incidence of melanoma in Japan to be 1.75 per 10,000. 4 Analysis of patients admitted to hospitals in Japan with melanoma from 2005 to 2017 indicated that the top three subtypes of melanoma were ALM (40.4%), SSM (20.5%), and NM (10.0%). 4 The demographic composition of the general US population and the US military differs. The United States is 61.0% White and 20.7% minorities, Black, Asians, American Indians, or Native Hawaiians, and 18.3% Hispanic. 5 The military, on the other hand, is 52.9% White, 31.0% minorities, and 16.1% Hispanic. 5 Of all military branches, the US Navy has the most minorities (38.0%). 5 Recent studies have demonstrated that members of the military are at increased risk of skin cancer, specifically melanoma. 5 This case of NM in a male veteran of African American and Japanese descent was selected due to the rare occurrence of NM in people of color (POC). NM in people with skin of color is understudied, as is the relationship between epidemiology and risk factors for melanoma in non-Caucasian populations. | CASE PRESENTATIONA 60-year-old male veteran whose mother was Japanese, and father was African American, presented for concerns of a growing lesion on his left lower abdomen. The lesion was present for several years, but had been

show abstract

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

Cited by 62 publications

References 46 publications

BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Nodular melanoma in an African American Japanese male

Contact Info

Product

Resources

About